Key clinical point: Secukinumab improved disease signs and symptoms of nonradiographic axial spondyloarthritis in patients who were tumor necrosis factor inhibitor naive or nonresponders with inadequate response to no more than one previous TNFi.
Major finding: At 16 weeks, an analysis of the overall population showed that 40.8% of patients in the secukinumab nonloading group had an 40% improvement in their Assessment of Spondyloarthritis International Society score, compared with 40.0% in those who got a loading dose and 28.0% with placebo (P less than .05 for both).
Study details: An analysis of 555 patients with nonradiographic axial spondyloarthritis in the PREVENT trial who were randomized to receive 150 mg of secukinumab with or without a loading dose or placebo over 52 weeks.
Disclosures: The PREVENT study was sponsored by Novartis, which markets secukinumab. Some of the authors reported relationships with Novartis and many other pharmaceutical companies. Four authors were employees of Novartis.
Deodhar AA et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract L21.